| Literature DB >> 25730172 |
Valentina Pirro1, Flavia Girolami, Veronica Spalenza, Giulia Gardini, Paola Badino, Carlo Nebbia.
Abstract
A chemometric class modelling strategy (unequal dispersed classes - UNEQ) was applied for the first time as a possible screening method to monitor the abuse of growth promoters in veal calves. Five serum biomarkers, known to reflect the exposure to classes of compounds illegally used as growth promoters, were determined from 50 untreated animals in order to design a model of controls, representing veal calves reared under good, safe and highly standardised breeding conditions. The class modelling was applied to 421 commercially bred veal calves to separate them into 'compliant' and 'non-compliant' with respect to the modelled controls. Part of the non-compliant animals underwent further histological and chemical examinations to confirm the presence of either alterations in target tissues or traces of illegal substances commonly administered for growth-promoting purposes. Overall, the congruence between the histological or chemical methods and the UNEQ non-compliant outcomes was approximately 58%, likely underestimated due to the blindness nature of this examination. Further research is needed to confirm the validity of the UNEQ model in terms of sensitivity in recognising untreated animals as compliant to the controls, and specificity in revealing deviations from ideal breeding conditions, for example due to the abuse of growth promoters.Entities:
Keywords: growth promoters; illegal treatments; multivariate analysis; serum biomarkers; veal calves
Mesh:
Substances:
Year: 2015 PMID: 25730172 PMCID: PMC4396443 DOI: 10.1080/19440049.2015.1011713
Source DB: PubMed Journal: Food Addit Contam Part A Chem Anal Control Expo Risk Assess ISSN: 1944-0057
Investigated analytes in serum and urines from veal calves (n = 24) of the ‘unknown’ group.
| Substance | Matrix | LOD (µg l−1) | LOQ (µg l−1) |
|---|---|---|---|
| 17β-Oestradiol | Serum | 0.03 | 0.03 |
| 17β-Testosterone | Serum | 1 | 2 |
| Progesterone | Serum | 0.06 | 0.15 |
| Ethinyloestradiol | Urine | 0.30 | 1.5 |
| Fluossimesterone | Urine | 0.55 | 1.5 |
| 16β-Hydroxystanozolol | Urine | 0.15 | 0.55 |
| Methylboldenone | Urine | 0.30 | 1.5 |
| Methyltestosterone | Urine | 0.30 | 1.5 |
| 17α-Nortestosterone | Urine | 0.30 | 1 |
| 17β-Nortestosterone | Urine | 0.30 | 1 |
| Stanozolol | Urine | 0.30 | 0.55 |
| 17α-Trenbolone | Urine | 0.25 | 1.5 |
| 17β-Trenbolone | Urine | 0.55 | 1.5 |
| 17α-Boldenone | Urine | 0.30 | 0.55 |
| 17β-Boldenone | Urine | 0.30 | 0.55 |
| Beclomethasone | Urine | 0.2 | 1.5 |
| Betamethasone | Urine | 0.2 | 1.5 |
| Dexamethasone | Urine | 0.2 | 1.5 |
| Flumethasone | Urine | 0.2 | 1.5 |
| Fluorometholone | Urine | 0.2 | 1.5 |
| Methylprednisolone | Urine | 0.2 | 1.5 |
| Prednisolone | Urine | 0.2 | 1.5 |
| Prednisone | Urine | 0.2 | 1.5 |
| Triamcinolone acetonide | Urine | 0.2 | 1.5 |
Serum biomarker values from veal calves in the control group (n = 50).
| Biomarker | Mean ± SD | Minimum | Median | Maximum |
|---|---|---|---|---|
| Osteocalcin (ng ml−1) | 13.73 ± 3.29 | 6.70 | 14.15 | 21.60 |
| Cortisol (ng ml−1) | 22.82 ± 7.1 | 8.81 | 22.03 | 48.53 |
| Inhibin (ng ml−1) | 3.32 ± 1.86 | 0.60 | 3.03 | 10.24 |
| Urea (mg dl−1) | 10.28 ± 3.03 | 5.00 | 10.00 | 20.00 |
| SAC (µmol HClO ml−1) | 352.63 ± 60.01 | 250.27 | 354.61 | 488.66 |
Note: SAC, serum antioxidant capacity.
Serum biomarker values from veal calves in the unknown group (n = 421).
| Biomarker | Mean ± SD | Minimum | Median | Maximum |
|---|---|---|---|---|
| Osteocalcin (ng ml−1) | 9.62 ± 2.17 | 0.10 | 9.42 | 9.83 |
| Cortisol (ng ml−1) | 24.83 ± 17.01 | 3.13 | 19.45 | 106.41 |
| Inhibin (ng ml−1) | 1.13 ± 0.63 | 0.04 | 1.04 | 6.36 |
| Urea (mg dl−1) | 14.21 ± 4.89 | 0.23 | 13.75 | 14.67 |
| SAC (µmol HClO ml−1) | 348.01 ± 72.12 | 3.47 | 342.21 | 661.04 |
Note: SAC, serum antioxidant capacity.
Figure 1. Distribution of the Mahalanobis distance (log values) for Group C and Group U animals. Blue figures = Group C; green figures = Group U, compliant animals; and red figures = Group U, non-compliant animals.
Figure 2. (colour online) Flow chart of the study.
Results of the histological evaluation (n = 52) and chemical analysis (n = 24) of selected samples from the ‘unknown veal calves’ group classified as ‘non-compliant’ with respect to the UNEQ class model based on the levels of five serum biomarkers.
| Histological evaluation | Chemical analysis | ||||
|---|---|---|---|---|---|
| Sample | Thymus | Prostate | Bulbourethral glands | Serum | Urinea |
| V01 | Suspect | Compliant | Compliant | Compliant | Compliant |
| V02 | Compliant | Compliant | Compliant | Compliant | 17β-BOLD detected < LOQ |
| V03 | Compliant | Compliant | Compliant | Compliant | Compliant |
| V04 | Uncertain | Compliant | Compliant | n.a. | n.a. |
| V05 | Uncertain | Compliant | Uncertain | n.a. | n.a. |
| V06 | Uncertain | Compliant | Compliant | n.a. | |
| V07 | Uncertain | Compliant | Compliant | Compliant | |
| V08 | Uncertain | Uncertain | Compliant | n.a. | n.a. |
| V09 | Compliant | Compliant | Compliant | n.a. | n.a. |
| V10 | Compliant | Compliant | Compliant | n.a. | n.a. |
| V11 | Compliant | Compliant | Compliant | Compliant | 17β-BOLD detected < LOQ |
| PRED detected < LOQ | |||||
| V12 | Uncertain | Uncertain | Compliant | Compliant | Compliant |
| V13 | Compliant | Compliant | Compliant | Compliant | Compliant |
| V14 | Uncertain | Compliant | Compliant | n.a. | n.a. |
| V15 | Suspect | Uncertain | Compliant | n.a. | n.a. |
| V16 | Compliant | Uncertain | Compliant | Compliant | Compliant |
| V17 | Uncertain | Compliant | Compliant | Compliant | Compliant |
| V18 | Uncertain | Compliant | Compliant | n.a. | n.a. |
| V19 | Compliant | Compliant | Compliant | n.a. | n.a. |
| V20 | Compliant | Compliant | Compliant | Compliant | 17β-BOLD detected < LOQ |
| V21 | Uncertain | Compliant | Compliant | n.a. | n.a. |
| V22 | Uncertain | Compliant | Compliant | Compliant | Compliant |
| V23 | Uncertain | Compliant | Compliant | n.a. | n.a. |
| V24 | Compliant | Compliant | Compliant | n.a. | n.a. |
| V25 | Compliant | Compliant | Compliant | Compliant | Compliant |
| V26 | Uncertain | Uncertain | Compliant | n.a. | n.a. |
| V27 | Compliant | Uncertain | Compliant | n.a. | n.a. |
| V28 | Uncertain | Compliant | Compliant | Compliant | Compliant |
| V29 | Uncertain | Compliant | Compliant | Compliant | Compliant |
| V30 | Suspect | Compliant | Compliant | n.a. | n.a. |
| V31 | Uncertain | Compliant | Compliant | Compliant | Compliant |
| V32 | Compliant | Compliant | Compliant | n.a. | n.a. |
| V33 | Compliant | Compliant | Compliant | n.a. | n.a. |
| V34 | Compliant | Uncertain | Compliant | Compliant | Compliant |
| V35 | Compliant | Compliant | Compliant | Compliant | Compliant |
| V36 | Compliant | Compliant | Compliant | n.a. | n.a. |
| V37 | Compliant | Compliant | Compliant | n.a. | n.a. |
| V38 | Compliant | Compliant | Compliant | Compliant | Compliant |
| V39 | Uncertain | Compliant | Compliant | n.a. | n.a. |
| V40 | Compliant | Compliant | Compliant | n.a. | n.a. |
| V41 | Compliant | Compliant | Compliant | n.a. | n.a. |
| V42 | Compliant | Compliant | Compliant | Compliant | 17β-BOLD detected < LOQ |
| V43 | Compliant | Compliant | Compliant | Compliant | 17β-BOLD detected < LOQ |
| V44 | Suspect | Compliant | Compliant | n.a. | n.a. |
| V45 | Compliant | Compliant | Compliant | n.a. | n.a. |
| V46 | Compliant | Compliant | Compliant | Compliant | Compliant |
| V47 | Compliant | Compliant | Compliant | Compliant | Compliant |
| V48 | Compliant | Compliant | Compliant | Compliant | PRED detected < LOQ |
| V49 | Compliant | Compliant | Compliant | Compliant | Compliant |
| V50 | Compliant | Compliant | Compliant | n.a. | n.a. |
| V51 | Compliant | Compliant | Compliant | n.a. | n.a. |
| V52 | Compliant | Compliant | Compliant | n.a. | n.a. |
Note: Serum samples were assayed for the presence of natural sexual steroids; urine specimens were analysed for the presence of synthetic sexual steroids and of corticosteroids. The full list of the searched analytes and the corresponding LOD and LOQ values is depicted in Table 1.
17β-BOLD, 17β-boldenone; PRED, prednisolone; n.a., not analysed.
The concentration of the identified analytes was in all cases higher than the LOD but lower than the LOQ.